Neurocrine Biosciences Inc vs Union Pacific Corporation — how do they compare? Neurocrine Biosciences Inc trades at $179.88 (market cap $17.40B), while Union Pacific Corporation trades at $295.5 (market cap $175.89B). The key difference: Union Pacific Corporation is far larger — about 10.1× Neurocrine Biosciences Inc's market cap, and Union Pacific Corporation pays a 1.86% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | UNP | |
|---|---|---|
Market Cap | $17.40B | $175.89B |
Sector | Health | Industrials |
52-Week High | $180.55 | $301.75 |
52-Week Low | $123.10 | $214.91 |
Enterprise Value | $16.49B | $206.36B |
Dividend Yield | — | 1.86% |
Trailing returns across standard periods
Latest headlines on both assets
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the U.S., UP generated roughly $22 billion of revenue in 2021 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and derives about 10% of its revenue hauling freight to and from Mexico.
Read more on UNP →